Showing 3531-3540 of 5560 results for "".
- Positive Topline Results from Pivotal Phase 3 Trial of Arcutis Biotherapeutics' Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-results-from-pivotal-phase-3-trial-of-arctuis-biotherapeutics-roflumilast-foam-in-scalp-and-body-psoriasis/2461359/Topline results from the ARRECTOR Pivotal Phase 3 trial evaluating Arcutis Biotherapeutics, Inc.'s roflumilast foam 0.3% were positive for the treatment of adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of S-
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages al
- Game On: IFPA Launches the “Explore Psoriatic Disease Together” Campaign to Build the IFPA Island on Animal Crossing: New Horizonshttps://practicaldermatology.com/news/game-on-ifpa-launches-the-explore-psoriatic-disease-together-campaign-to-build-the-ifpa-island-on-animal-crossing-new-horizons/2461328/The International Federation of Psoriatic Disease Associations (IFPA) is launching a campaign to build the IFPA Island on the Nintendo video game, Animal Crossing: New Horizons. This new campaign is called “Explore Psoriatic Disease Together” and calls on the psoriatic disea
- Study: Colorescience Total Eye Firm & Repair Cream Improves Appearance of Overall Periorbital Areahttps://practicaldermatology.com/news/study-colorescience-total-eye-firm-repair-cream-improves-appearance-of-overall-periorbital-area/2461316/Colorescience Total Eye Firm & Repair Cream improves periorbital wrinkles, dryness, laxity and dark circles, according to a study in the Journal of Cosmetic Dermatology. Results of the clinical study
- Senté Launches Cysteamine HSA Pigment & Tone Correctorhttps://practicaldermatology.com/news/sente-launches-cysteamine-hsa-pigment-tone-corrector/2461301/Cysteamine HSA Pigment & Tone Corrector from Senté has launched to safely and effectively target pigmentation in all skin tones. The hydroquinone-free formula is safe for long-term use and formulated for all skin types, including dry or sensitive skin.
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formula
- Survey: Chronic Hive Patients Unsatisfied with Quality of Life, Carehttps://practicaldermatology.com/news/survey-chronic-hive-patients-unsatisfied-with-quality-of-life/2461271/Only one-fourth of patients with chronic hives are satisfied with their current quality of life, according to a recent survey conducted by